Related Experiment Video
Updated: May 16, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
Targeting the right regulatory T-cell population for tumor immunotherapy
Vivian L Weiss1, Timothy H Lee, Elizabeth M Jaffee
1The Sidney Kimmel Cancer Center; Johns Hopkins University School of Medicine; Baltimore, MD USA ; Department of Oncology; Johns Hopkins University School of Medicine; Baltimore, MD USA ; Graduate Program in Immunology; Johns Hopkins School of Medicine; Baltimore, MD USA.
Abstract:
Regulatory T cells (Tregs) that suppress tumor-specific T cell-mediated immune responses are the subject of an intense wave of investigation. We recently reported that a subset of Tregs, namely effector/memory CD25(low) cells, are responsible for suppressing high avidity tumor-specific T cells in mouse mammary tumors. Here, we discuss additional findings that clarify this mechanism of Treg-mediated immunosuppression.
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
